JAK2V617F Activating Mutation and Silencing of JAK Inhibitor SOCS2 Pathogenic Mechanisms for Myeloproliferative Disorders

  • Überblick


    Datum: 30.05.2008, 12:15

    Veranstaltungsort

    Forum X1.04

    Referent

    Dr. Hilmar Quentmeier, DSMZ

    Gastgeber

    Dr. Hansjörg Hauser